(JNJ) Johnson & Johnson - Ratings and Ratios

Johnson & Johnson, a multinational healthcare giant, operates through two primary segments: Innovative Medicine and MedTech. The Innovative Medicine division focuses on pharmaceutical products addressing immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. Key offerings include treatments for rheumatoid arthritis, HIV/AIDS, schizophrenia, and various cancers. The MedTech segment provides medical devices for electrophysiology, heart recovery, circulatory restoration, neurovascular care, orthopedics, surgery, and vision care, including ACUVUE contact lenses and TECNIS intraocular lenses. The company distributes its products globally through a network of wholesalers, hospitals, retailers, and healthcare professionals. Founded in 1886, Johnson & Johnson is headquartered in New Brunswick, New Jersey, and is known for its diversified portfolio and commitment to innovation in healthcare.

Johnson & Johnson (NYSE: JNJ) is a common stock listed on the New York Stock Exchange, classified under the Pharmaceuticals sub-industry. The company has a market capitalization of $370.2 billion, with a price-to-earnings ratio of 26.53 and a forward P/E of 14.53. Its price-to-book ratio is 5.18, and the price-to-sales ratio is 4.17. The return on equity stands at 19.68%. Key technical indicators include an average 20-day volume of 10,766,495 shares, a last price of $157.47, and moving averages of SMA20 at 156.77, SMA50 at 159.49, and SMA200 at 154.90. The Average True Range (ATR) is 3.94. Support levels are identified at 157.2, 151.6, and 143.1, while resistance levels are at 163.0 and 200.0.

3-Month Forecast: - SMA20: 156.77 - SMA50: 159.49 - SMA200: 154.90 - ATR: 3.94 - Average Volume 20d: 10,766,495 - Last Price: 157.47 - Market Cap: $370.201B USD - P/E: 26.53 - P/E Forward: 14.53 - P/B: 5.18 - P/S: 4.17 - RoE: 19.68 - Technical Outlook: The stock is trading above its SMA200, indicating long-term bullish momentum. However, the SMA50 is above the SMA20, suggesting a potential near-term consolidation. With an ATR of 3.94, volatility is moderate. - Fundamental Outlook: The forward P/E of 14.53 signals expectations of earnings growth. The high P/B ratio reflects strong brand value and intangible assets. The RoE of 19.68 highlights efficient profitability. - Price Targets: Based on technical and fundamental data, the stock is expected to range between 151.6 and 163.0 over the next three months, with potential upside driven by earnings growth and downside limited by strong support at 151.6.